Prognostic and predictive values of long non-coding RNA LINC00472 in breast cancer
Metrics: PDF 2918 views | HTML 3555 views | ?
Yi Shen1, Dionyssios Katsaros2, Lenora W. M. Loo1, Brenda Y. Hernandez1, Clayton Chong1, Emilie Marion Canuto2, Nicoletta Biglia3, Lingeng Lu4, Harvey Risch4, Wen-Ming Chu5, Herbert Yu1
1Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA
2Department of Surgical Sciences, Azienda Ospedaliero-Universitaria, Turin, Italy
3Department of Surgical Sciences, University of Turin, Torino, Italy
4Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA
5Cancer Biology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA
Herbert Yu, e-mail: [email protected]
Keywords: lincRNA, breast, LINC00472
Received: January 05, 2015 Accepted: February 07, 2015 Published: March 25, 2015
LINC00472 is a novel long intergenic non-coding RNA. We evaluated LINC00472 expression in breast tumor samples using RT-qPCR, performed a meta-analysis of over 20 microarray datasets from the Gene Expression Omnibus (GEO) database, and investigated the effect of LINC00472 expression on cell proliferation and migration in breast cancer cells transfected with a LINC00472-expressing vector. Our qPCR results showed that high LINC00472 expression was associated with less aggressive breast tumors and more favorable disease outcomes. Patients with high expression of LINC00472 had significantly reduced risk of relapse and death compared to those with low expression. Patients with high LINC00472 expression also had better responses to adjuvant chemo- or hormonal therapy than did patients with low expression. Results of meta-analysis on multiple studies from the GEO database were in agreement with the findings of our study. High LINC00472 was also associated with favorable molecular subtypes, Luminal A or normal-like tumors. Cell culture experiments showed that up-regulation of LINC00472 expression could suppress breast cancer cell proliferation and migration. Collectively, our clinical and in vitro studies suggest that LINC00472 is a tumor suppressor in breast cancer. Evaluating this long non-coding RNA in breast tumors may have prognostic and predictive value in the clinical management of breast cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.